Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age

Go back to Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
Pfizer Inc. (NYSE: PFE) Delayed: 30.20 +0.35 (1.17%)
Previous Close $29.85    52 Week High $37.39 
Open $30.05    52 Week Low $28.25 
Day High $30.36    P/E 18.30 
Day Low $29.88    EPS $1.65 
Volume 14,755,889